RATIONALE: Combining calcitriol with dexamethasone may increase the effectiveness of therapy by making cancer cells more sensitive to dexamethasone. PURPOSE: Phase I trial to study the effectiveness of calcitriol combined with dexamethasone in treating patients who have prostate cancer that has not responded to previous hormone therapy.

Condition	Treatment or Intervention	Phase
stage III prostate cancer stage IV prostate cancer adenocarcinoma of the prostate recurrent prostate cancer	Procedure: biological response modifier therapy  Procedure: hormone therapy  Procedure: steroid therapy  Procedure: endocrine therapy  Procedure: differentiation therapy  Drug: calcitriol  Drug: dexamethasone	Phase I

Further Study Details: 

OBJECTIVES: I. Determine the maximum tolerated dose of calcitriol administered alone and in combination with dexamethasone in patients with hormone-refractory prostate cancer. II. Determine the pharmacokinetics of calcitriol with and without dexamethasone in these patients.

PROTOCOL OUTLINE: This is a dose-escalation study of calcitriol. In the first stage of the study, cohorts of 3-6 patients receive escalating doses of oral calcitriol on days 1-3. Dose escalation continues until the maximum tolerated dose (MTD) is determined. In the second stage, patients receive escalating doses of oral calcitriol on days 1-3 and a fixed dose of oral dexamethasone on days 0-4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity. Dose escalation continues until the MTD is determined. Six additional patients may receive calcitriol and dexamethasone at one dose level below the MTD determined in the second stage, to confirm the MTD. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Histologically confirmed adenocarcinoma of the prostate with progressing regional or metastatic disease despite primary hormonal therapy (bilateral orchiectomy, estrogen, or luteinizing hormone-releasing hormone (LHRH) therapy with or without simultaneous antiandrogen)

Documented new lesions or rising PSA (at least 50% increase on 3 measurements more than 2 weeks apart) after prior antiandrogen or progestational agent, or other hormonal agent cessation

--Prior/Concurrent Therapy--

Biologic therapy: Concurrent epoetin alfa for anemia allowed

Chemotherapy: Not specified

Endocrine therapy:

• See Disease Characteristics
• At least 28 days since prior antiandrogens or progestational agents
• Concurrent testicular androgen suppression with an LHRH analog (leuprolide or goserelin) allowed in non-orchidectomized patients

Radiotherapy: No concurrent radiotherapy

Surgery: Not specified

Other: No concurrent bisphosphonates

--Patient Characteristics--

Age: 18 and over

Performance status: ECOG 0-2

Life expectancy: Not specified

Hematopoietic:

• WBC greater than 3,500/mm3
• Absolute neutrophil count greater than 1,500/mm3
• Platelet count greater than 100,000/mm3

Hepatic:

• Bilirubin less than 2.0 mg/dL
• SGOT less than 4 times upper limit of normal

Renal: Creatinine no greater than 1.8 mg/dL

Other:

• No uncontrolled diabetes mellitus
• Fertile patients must use effective double barrier contraception for at least 1 week before, during, and at least 2 weeks after study

Pennsylvania
      University of Pittsburgh Cancer Institute, Pittsburgh,  Pennsylvania,  15213-3489,  United States

Study chairs or principal investigators

Gurkamal Chatta,  Study Chair,  University of Pittsburgh Cancer Institute   

Study ID Numbers:  CDR0000068457; UPITTS-99044; UPITTS-IRB-990606
Record last reviewed:  June 2003
Last Updated:  October 13, 2004
Record first received:  February 2, 2001
ClinicalTrials.gov Identifier:  NCT00010231
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08